Capital International, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Capital International, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$83.14 - $145.99 $1.94 Million - $3.41 Million	-23,350 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $879,098 - $1.14 Million	-7,986 Reduced 25.49%	23,350 $2.77 Million
Q4 2021 Feb 14, 2022	SELL	$99.73 - $148.48 $44.1 Million - $65.6 Million	-442,142 Reduced 93.38%	31,336 $4.32 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $7.34 Million - $10.3 Million	-74,299 Reduced 13.56%	473,478 $65.8 Million
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $2.34 Million - $3.74 Million	-35,590 Reduced 6.1%	547,777 $53.2 Million
Q1 2021 May 14, 2021	SELL	$64.07 - $91.75 $4.74 Million - $6.79 Million	-74,013 Reduced 11.26%	583,367 $39.9 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $5.18 Million - $7.82 Million	-79,609 Reduced 10.8%	657,380 $56.3 Million
Q3 2020 Nov 13, 2020	SELL	$59.04 - $77.95 $19.8 Million - $26.1 Million	-334,877 Reduced 31.24%	736,989 $47.9 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $347,336 - $888,755	11,973 Added 1.13%	1,071,866 $78.4 Million
Q1 2020 May 15, 2020	SELL	$27.51 - $57.29 $2.21 Million - $4.6 Million	-80,208 Reduced 7.04%	1,059,893 $36.1 Million
Q4 2019 Feb 18, 2020	SELL	$40.86 - $57.65 $46,662 - $65,836	-1,142 Reduced 0.1%	1,140,101 $62.1 Million
Q3 2019 Nov 14, 2019	BUY	$37.38 - $49.47 $40.5 Million - $53.6 Million	1,083,931 Added 1891.28%	1,141,243 $47.6 Million
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $2.28 Million - $3.84 Million	57,312 New	57,312 $2.51 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.